NCT05443685View on ClinicalTrials.gov

ADX-629 Therapy for Sjogren-Larsson Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Sjogren-Larsson Syndrome
Interventions
DRUG

ADX-629

"Particpants 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Participants 5-9 years old will be administered ADX-629 125 mg tablets twice daily."

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER